A Protein in Stomach Juice and the Zagreb Lab That Spent Thirty Years Studying It

Most peptides in a research catalog have a tidy origin story: a hormone is discovered, its sequence is solved, an analog is built. BPC-157 has a stranger one. It starts with a question that sounds almost too simple to be a research program: why doesn’t the stomach digest itself?

The question behind the peptide

Gastric juice is acidic enough to dissolve a lot of things, yet the stomach lining survives it daily. Physiologists had long pointed to mucus, bicarbonate and prostaglandins as the defenses. In the late 1980s and early 1990s, a group at the University of Zagreb School of Medicine, led by Predrag Sikirić, took a different angle. They asked whether gastric juice itself contains a protective protein, something that does not merely neutralize acid but acts on the tissue.

Their answer was a protein they called body protection compound, or BPC, isolated from human gastric juice. The fragment that became the workhorse of the program is a 15-amino-acid stretch called BPC-157, often described as a “stable gastric pentadecapeptide.” Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight a little over 1,400 daltons.

Two details of that sequence matter to a chemist. First, it is rich in proline, which tends to make peptides more resistant to many proteases. Second, the authors reported that the fragment stays intact in gastric juice for an extended period, which is part of why it earned the word “stable” in its description. That stability is a property of the molecule in a test tube; it does not by itself tell you anything about what happens in a living animal.

What the early papers looked at

The first wave of publications from the Zagreb group used rodent models, and the themes were consistent:

• Gastrointestinal lesions. Rats given experimental ulcers (induced by ethanol, NSAIDs, or surgical models) were compared with controls.
• Tendon and muscle injury. Transected Achilles tendon models in rats became a signature experiment.
• Fistula and anastomosis models. Surgical connections in the gut, and how well they healed.
• Organ-protection models. Liver, pancreas and other tissues challenged by toxins.

Across these papers the group proposed that BPC-157 interacts with several signaling systems, including nitric oxide pathways and growth-factor signaling related to blood vessel formation. If you have read about these mechanisms elsewhere, it is worth knowing that most of the proposed pathways were described by the same laboratory and its collaborators.

The honest part: a literature with one center of gravity

This is the part of the story that a careful reader should sit with. A large fraction of the published BPC-157 work comes from Sikirić’s group and its close collaborators. That does not make the findings wrong. Plenty of important science began in a single productive lab. But it changes how you should weigh the evidence, for three reasons.

1. Independent replication is the gold standard. A result seen by a second, unconnected lab with its own animals, reagents and analysts is much stronger than a result seen repeatedly by one team.
2. Models and protocols tend to be shared within a group. If a quirk of the injury model or the scoring system inflates an effect, every paper from that group inherits it.
3. The translational record is thin. Despite decades of animal work, the amount of well-controlled human data is small, and anything you read that sounds like a settled human conclusion deserves suspicion.

None of this is a reason to ignore the compound. It is a reason to read the primary papers, note which groups produced them, and design your own experiments with proper controls rather than assuming the literature’s effect sizes will transfer.

What this means at the bench

If you are planning in vitro or animal-model work with BPC-157, the origin story translates into a few practical habits:

• Identity first. Because the peptide is a short, proline-rich sequence, confirm the mass-spec identity on your batch’s certificate of analysis rather than relying on the label.
• Match your question to the model. The Zagreb papers use specific injury models. If you change the model, you cannot assume the literature applies.
• Write down your lot number. If you later see an effect fade, lot-to-lot variation is one of the first things to check.
• Include vehicle and negative controls. Especially with a compound whose literature leans heavily on one lab, your own controls are what make your result credible.

The takeaway

BPC-157 is a good example of how a research field can be both genuinely interesting and genuinely unfinished. A question about how the stomach protects itself produced a fragment, a long line of animal studies, and a literature that still needs wider independent testing. That is exactly the situation where careful bench work has the most to add.

If BPC-157 is part of your research plan, you can view the compound, its specifications and its batch certificate of analysis on the BPC-157 10mg product page.

All Lucid Aminos products are sold strictly for laboratory research use. They are not drugs, dietary supplements or food, and they are not for human or veterinary use. This article is educational, describes published research, and is not medical advice.